Drug intelligence / Profile preview

VTX-ID24

Development stage: Preclinical
Lead developer: Voltron Therapeutics
Modality: Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

VTX-ID24 is a preclinical-stage vaccine candidate being developed by **Voltron Therapeutics** for the prevention of **influenza**. The program is notable for receiving government funding and is currently in the discovery/preclinical phase. While specific details regarding the vaccine's platform or the specific influenza strains targeted have not been publicly disclosed in the provided pipeline documentation, the candidate is part of Voltron's infectious disease portfolio, which typically leverages proprietary technology to elicit robust immune responses against viral pathogens.

Targets

PSCA (Prostate stem cell antigen)

Beyond the preview

Go deeper on VTX-ID24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTX-ID24.

Explore the full profile